Revance releases two RT001 Phase 2b trials results
The two multi-center, double-blind, randomised, controlled studies showed that RT001 was well tolerated and demonstrated efficacy versus controls. Revance said that the first study enrolled 90 subjects and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.